Tirzepatide

Dual GIP / GLP-1 receptor agonist (Mounjaro / Zepbound) — stronger weight loss than Semaglutide.

Tirzepatide hits two gut-hormone receptors instead of one — GLP-1 plus GIP — and the combination produces stronger appetite suppression and weight loss (~20%) than Semaglutide, often with better GI tolerance at equivalent results. It's become the standard "upgrade" for people who plateau on or don't tolerate Sema. Same class cautions apply: titrate up slowly, and protect lean mass with protein and resistance training.

Dose

Titrate 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg per week.

Reconstitute

10 mg + 2 mL = 5 mg/mL. 5 units = 1.25 mg, 10 units = 2.5 mg.

Schedule

Weekly, 16+ week titration.

Half-life

~5 days.

Timing

Same day each week.

Risks

Same class profile as Sema. Lean-mass loss without strength training. Early nausea common.

Educational reference — not medical advice. Many peptides are not approved for the uses discussed; verify status in your jurisdiction and decide anything here with a qualified clinician.

within Weight Loss & GLP Class